secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0001104659-25-097739
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics unveils positive preclinical data for VCN-12, showing superiority over VCN-01
--------------------------------------------------------------------------------

- VCN-12 showed up to 13.7x greater cytotoxicity than VCN-01 across multiple cancer cell lines in vitro.
- In HP-1 pancreatic tumor hamster model, VCN-12 significantly reduced growth in both injected and non-injected tumors.
- Complete tumor regression in 2/9 hamsters; those animals rejected tumor re-challenge 43 days later.
- VCN-12 incorporates bee hyaluronidase (higher activity) and parasporin-2 to enhance immunogenic cell death.
- Toxicity profile in mice similar to VCN-01; further preclinical studies planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925097739/0001104659-25-097739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925097739/tm2528131d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-097739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer